About Princess Máxima Center for Pediatric Oncology
www.prinsesmaximacentrum.nl
When a child is seriously ill from cancer, only one thing matters: a cure. That is why in the Princess Máxima Center for Pediatric Oncology, we work together with passion, pushing the boundaries to improve survival and quality of life for children with cancer.
Now, and in the long term. Because children have their entire lives ahead of them. The Princess Máxima Center for Pediatric Oncology is no ordinary hospital but a research hospital, the biggest childhood cancer center in Europe.
Here, more than 400 scientists and 900 healthcare professionals work closely with Dutch and international hospitals to find new treatments and new perspectives for a cure. In this way, we offer children today the very best care, and take important steps toward improving survival for the children who are not yet cured.
About ESQlabs
www.esqlabs.com
ESQlabs, led by CEO Dr. Stephan Schaller, provides modelling and simulation solutions in the field of pharmacokinetic/pharmacody- namic and PBPK modeling, as well as physiology-based quantita- tive systems pharmacology. It utilizes the open source OSP Suite, to which it actively contributes in development and participates in the user-community.
ESQlabs currently offers various services, including model develop- ment and refinement, data integration, and consulting for clients in life sciences and pharmacology. ESQlabs has a team of over 30 scientists with extensive expertise in areas such as modeling, statistics, pharmacology, and software development.
The application scope and user base of the OSP Suite for creating digital representations of human biology is constantly growing. Principial Scientist Christian Maass, PhD, is leading the platform development for digital twins for organ-on-chip and micro-physio- logical systems, whose expertise will be essential in the project.
About Bambino Gesù Children’s Hospital
www.ospedalebambinogesu.it
The Bambino Gesù Children’s Hospital, an institution belonging to the Holy See, is one of the largest European pediatric hospitals and research centers. The research laboratories of the hospital are equipped with the most modern technologies for cellular, molecular and genetic research and with a Pharmaceutical GMP facility dedicated to the production of drugs for advanced therapies.
In particular, the Pediatric Onco-hematology Research Area develops new molecular diagnostic approaches aimed at the stratification of pediatric cancer patients and leads national and international studies focused on the development of innovative cell and gene therapy protocols, from bench to bed side, running Phase I/II clinical trials.
Every year, around 400 cancer patients come to OPBG for treatment. Of those patients, 120 are patients affected by tumors of the central nervous system. Maria Vinci, PhD, leads the Pediatric High-Grade Glioma group. Her team has long lasting expertise on the generation of primary patient-derived cell models. The development and preclinical applications of diffuse midline glioma models will be vital to demonstrate the power of δypha system.
About Biosystems
www.syncbiosystems.com
Founded in 2022, Sync Biosystems aims to increase the level of control over existing cell culture models by leveraging high-tech engineering.
Having experienced cell culture biologists and engineers, Sync Biosystems ensures their solutions are plug-and-play so end users do not need to change the way that they work.
While developing the fluidic control product, the team has an in-house system to provide contract research service to customers. Sync Biosystems is located at the Leiden Bio Science Park, the Netherlands, and is part of the Demcon group.
About Charles River Laboratories
www.criver.com
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
About Demcon
www.demcon.com
Demcon (1.100+ employees) develops, produces, and supplies technology and innovative products.
The Demcon group has locations in Best, Enschede, Delft, Groningen, Leiden, Maastricht (the Netherlands), Münster (Germany), Tokyo (Japan), and Singapore.
The company was born out of the founders’ passion for combining creativity and technical skills to solve complex issues of a technological and social nature. In addition, Demcon is committed to stimulating entrepreneurship, and investing in talent and education.